<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220712</url>
  </required_header>
  <id_info>
    <org_study_id>031-13-005</org_study_id>
    <nct_id>NCT02220712</nct_id>
  </id_info>
  <brief_title>A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot
      formulation in patients with schizophrenia after repeated administration by injection into
      the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration-time profiles (including C28d of plasma aripiprazole and its main metabolite OPC-14857)</measure>
    <time_frame>Day1, 2, 3, 4, 5,6, 8, 12, 15, 20, 22, 29, 57,85, 113, 114, 115, 116, 117, 118, 120, 124, 127, 134, 141, 155, 169</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Drug: OPC-14597 IMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-14597 IMD</intervention_name>
    <description>Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals</description>
    <arm_group_label>Drug: OPC-14597 IMD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of schizophrenia as defined by Diagnostic and Statistical
             Manual (DSM)-IV-Text Revision (TR) (295.30, 295.10, 295.20, 295.90, 295.60)

          -  Patients who have provided written informed consent by themselves (If the patient is a
             minor, written consent from a legal representative must be obtained in addition to the
             patient's own written informed consent.)

          -  Patients, both male and female, aged 18 years or older, but younger than 65 years, at
             the time of obtaining informed consent

          -  Patients with a body mass index of 18.5 or higher and lower than 35.0

          -  Patients whose mental condition is stable or well maintained for 2 weeks or more
             without any change to dosage regimen for their non-aripiprazole oral atypical
             antipsychotic monotherapy prior to obtaining informed consent

          -  Patients who have received aripiprazole in the past

        Exclusion Criteria:

          -  Patients diagnosed as having a mental disorder other than schizophrenia, as defined by
             DSM-IV-TR criteria.

          -  Patients with a history or complication of diabetes.

          -  Patients with hepatic, renal, cardiac, or hematopoietic disorders.

          -  Female patients who are pregnant or lactating, who may possibly be pregnant, who wish
             to become pregnant, or male patients whose partner wishes to become pregnant.

          -  Patients who have a drug allergy or drug hypersensitivity

          -  Patients for whom clozapine has been ineffective, patients who have responded only to
             clozapine, or patients who are currently being treated with clozapine.

          -  Patients with a complication of Parkinson's Disease (excluding drug-induced
             Parkinsonism).

          -  Patients with a history or a complication of neuroleptic malignant syndrome,
             rhabdomyolysis, tardive dyskinesia, paralytic ileus or water intoxication.

          -  Patients with a history or a complication of psychological or behavioral abnormalities
             associated with use of psychoactive substances (abuse of alcohol, narcotics, or
             organic solvent, etc).

          -  Patients with a history or a complication of suicide attempt or self-injury within 52
             weeks prior to obtaining informed consent.

          -  Patients with a history of or a complication of convulsive disorder such as epilepsy.

          -  Patients with a history of or a complication of organic brain disorder including
             cerebrovascular disease.

          -  Patients with a history or a complication of granulocytopenia or agranulocytosis.

          -  Patients who have received electro-convulsive therapy (ECT) within 12 weeks prior to
             obtaining informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-ichi Hashimoto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Deltoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

